Teva Pharma (TEVA) Reports In-Line Q2 EPS; Lowers Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Teva Reports Second Quarter 2021 Financial Results
July 28, 2021 7:00 AM EDTRevenues of $3.9 billion GAAP diluted EPS of $0.19 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $218 million Free cash flow of $625 million 2021 revenue outlook revised lower to reflect ongoing impact of COVID-19; all other key components reaffirmed: Net revenues of $16.0 - $16.4 billion vs. previous range of $16.4 - $16.8 billion Adjusted EBITDA of $4.8 - $5.1 billion EPS of $2.50 - $2.70 Free cash flow of $2.0 - $2.3 billion
TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:... More
